Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) FCF Margin (2022 - 2025)

Arcutis Biotherapeutics has reported FCF Margin over the past 4 years, most recently at 20.86% for Q4 2025.

  • Quarterly results put FCF Margin at 20.86% for Q4 2025, up 2194.0% from a year ago — trailing twelve months through Dec 2025 was 1.71% (up 5602.0% YoY), and the annual figure for FY2025 was 1.7%, up 6573.0%.
  • FCF Margin for Q4 2025 was 20.86% at Arcutis Biotherapeutics, up from 1.77% in the prior quarter.
  • Over the last five years, FCF Margin for ARQT hit a ceiling of 20.86% in Q4 2025 and a floor of 9338.07% in Q3 2022.
  • Median FCF Margin over the past 4 years was 112.02% (2024), compared with a mean of 1200.09%.
  • Biggest five-year swings in FCF Margin: skyrocketed 919124bps in 2023 and later surged 1522bps in 2025.
  • Arcutis Biotherapeutics' FCF Margin stood at 2404.19% in 2022, then surged by 83bps to 415.87% in 2023, then surged by 100bps to 1.08% in 2024, then surged by 2035bps to 20.86% in 2025.
  • The last three reported values for FCF Margin were 20.86% (Q4 2025), 1.77% (Q3 2025), and 0.3% (Q2 2025) per Business Quant data.